Vericel Corp revenue
Vericel Corp's revenue was $276m in fiscal 2025, up 16.5% on the year before. Since fiscal 2009 ($182,000) it has grown at a compound 58.1% a year. Over the last twelve months it was $306m.
Revenue history
| Fiscal year | 2009Jun 2009 | 2010Jun 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 29 | 51 | 54 | 64 | 91 | 118 | 124 | 156 | 164 | 198 | 237 | 276 | 306 |
| Growth on the year before | — | −51.1% | −79.8% | +16.7% | −9.5% | +>999% | +77.7% | +6.3% | +17.5% | +42.1% | +29.7% | +5.4% | +25.8% | +5.2% | +20.2% | +20.1% | +16.5% | — |
| Gross profit | — | — | — | 0 | 0 | 12 | 25 | 26 | 34 | 59 | 80 | 84 | 106 | 110 | 136 | 172 | 206 | 228 |
| Gross margin | — | — | — | 71.4% | 78.9% | 39.9% | 48.3% | 47.9% | 52.5% | 64.6% | 68.1% | 67.8% | 67.9% | 66.8% | 68.6% | 72.6% | 74.4% | 74.6% |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Vericel Corp | $306m | 23.0% | 19.8% |
| Adaptive Biotechnologies Corp | $308m | 50.1% | 17.6% |
| Vir Biotechnology, Inc. | $303m | 1495.9% | -14.8% |
| Arvinas, Inc. | $317m | -15.0% | 26.1% |
| Syndax Pharmaceuticals Inc | $290m | 159.7% | 177.8% |
| Iovance Biotherapeutics, Inc. | $325m | 34.5% | — |
Compare with peers
- Adaptive Biotechnologies Corp revenue
- Vir Biotechnology, Inc. revenue
- Arvinas, Inc. revenue
- Syndax Pharmaceuticals Inc revenue
- Iovance Biotherapeutics, Inc. revenue
Head to head: ADPT vs VCELVCEL vs VIRARVN vs VCELIOVA vs VCEL
More: Biotechnology stocks compared, Health Care sector, rankings of US companies